highperformr logo

Context Therapeutics's Overview

Total employees21
HeadquartersPhiladelphia
Founded2015

Context Therapeutics Inc. (formerly NASDAQ: CNTX) was a clinical-stage biopharmaceutical company dedicated to advancing treatments for hormone-driven women's cancers, including breast, ovarian, and endometrial cancers. Their lead product candidate was Onapristone XR (ONA-XR), an oral progesterone receptor antagonist. In late 2023, following the termination of a planned merger with PDS Biotechnology, Context Therapeutics announced its intent to wind down operations, discontinue further development of its clinical programs, and explore strategic alternatives for its assets.

Where is Context Therapeutics's Headquarters?

HQ Function

Served as the central hub for corporate administration, clinical development oversight, research collaborations, and strategic decision-making.

Notable Features:

Likely located within Philadelphia's uCity Square, a hub for life sciences and technology companies, offering modern lab and office facilities.

Work Culture:

As a clinical-stage biotech, the culture was likely mission-driven, fast-paced, and collaborative, with a strong emphasis on scientific innovation and patient impact.

HQ Significance:

The Philadelphia location provided access to a rich ecosystem of academic research institutions, talent, and potential partners in the biopharmaceutical industry.

Values Reflected in HQ: The headquarters likely aimed to reflect values of innovation, scientific rigor, and a commitment to addressing unmet medical needs in women's oncology.

Location:

While headquartered in the United States, Context Therapeutics's clinical trial activities for its product candidates may have involved sites and investigators internationally, typical for biopharmaceutical development. However, the company did not have a substantial physical global office infrastructure, focusing its core operations in the US prior to its wind-down.

Street Address:

3675 Market Street, Suite 200

City:

Philadelphia

State/Province:

PA

Country:

USA

Context Therapeutics's Global Presence

N/A

Address: N/A

N/A

Buying Intent Signals for Context Therapeutics

Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.

Notable news
Hiring actively
Corporate Finance
Corporate Finance
Corporate Finance
Corporate Finance
Corporate Finance
*Example signal, not calculated in real time

Executive Team of Context Therapeutics

As of April 2025, Context Therapeutics' leadership includes:

Martin Lehr - Former Co-Founder & Chief Executive Officer
Tarek Sahmoud, MD, PhD - Former Chief Medical Officer
Jennifer Minai-Azary - Former Chief Financial Officer
Alex Levit - Former Chief Legal Officer

Investors of Context Therapeutics

Context Therapeutics has been backed by several prominent investors over the years, including:

Public shareholders (formerly NASDAQ: CNTX)
Various institutional investors (during its time as a public company)
Life sciences-focused venture capital firms (during private funding rounds prior to IPO)

Executive New Hires/Exits in the Last 12 Months

Hire0
Exits4

Following the announcement in December 2023 to wind down operations, it is anticipated that the key executive team members have transitioned out of their roles as the company ceases its primary activities. No new executive hires are expected under these circumstances.

Departures

Martin Lehr, Expected departure as CEO following the company's decision to wind down operations.
Tarek Sahmoud, MD, PhD, Expected departure as CMO as clinical development programs were discontinued.
Jennifer Minai-Azary, Expected departure as CFO during the operational wind-down process.
Alex Levit, Expected departure as CLO during the operational wind-down process.

Technology (Tech Stack) used by Context Therapeutics

Discover the tools Context Therapeutics uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.

Context Therapeutics Email Formats and Examples

Common email formats for companies like Context Therapeutics typically involved combinations of first name, last name, or initials. Given the company's wind-down, these email addresses are likely no longer active.

[first_initial][last]@contexttherapeutics.com

Format

mlehr@contexttherapeutics.com (example for former CEO Martin Lehr, likely inactive)

Example

0%

Success rate

News and media

GlobeNewswireDecember 28, 2023

Context Therapeutics Announces Termination of Merger Agreement with PDS Biotechnology and Intent to Wind Down Operations

Context Therapeutics Inc. announced the mutual termination of its previously announced merger agreement with PDS Biotechnology Corporation. Concurrently, Context’s Board of Directors authorized a plan to wind down the Company’s operations, discontinue further development of its clinical-stage asset ONA-XR and other preclinical programs, and pursue the sale or disposition of its assets. The Company also intends to voluntarily delist its common stock from The Nasdaq Capital Market....more

GlobeNewswireJuly 24, 2023

Context Therapeutics and PDS Biotechnology Announce Definitive Merger Agreement

Context Therapeutics Inc. and PDS Biotechnology Corporation (Nasdaq: PDSB) announced they entered into a definitive merger agreement to combine the companies in an all-stock transaction. The proposed merger aimed to create a company focused on advancing PDS Biotech's pipeline of clinical-stage immunotherapies and infectious disease vaccines....more

GlobeNewswireOctober 5, 2022

Context Therapeutics Announces Preliminary Data from Ongoing Phase 2 Trial of Onapristone XR in Combination with Anastrozole to Treat ER+, PR+, HER2- Metastatic Breast Cancer

Context Therapeutics Inc. announced preliminary clinical data from the ongoing Phase 2 OATH trial evaluating onapristone extended-release (ONA-XR) in combination with anastrozole for the treatment of estrogen receptor-positive (ER+), progesterone receptor-positive (PR+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (MBC) in postmenopausal women who have progressed on prior CDK4/6 inhibitor therapy....more

Highperformr’s free tools for company research

Explore Employees by Region or Country

See where a company’s workforce is located, by country or region.

View Funding Details

View past and recent funding rounds with amounts and investors.

Understand Revenue Insights

Understand company revenue estimates and financial scale.

Track Active Job Openings

Track active roles and hiring trends to spot growth signals.

Review Product and Offerings

Discover what a company offers—products, platforms, and solutions.

Get SIC or NAICS Codes

Get the company’s official SIC and NAICS classifications.

Analyze Website Traffic Trends

Analyze visitor volume, engagement, and top traffic sources.

Discover Social Profiles and Engagement

Explore LinkedIn, Twitter, and other active social profiles.

Identify Top Competitors

Identify top competitors based on similar business traits.

Research and Discover Companies with Highperformr — Smarter, Faster

Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.

Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.

  • Track intent signals to find buyers who are actively in-market
  • Enrich contacts and companies instantly, no need to switch tools
  • Automate workflows to stay ahead of every change
  • Connect your CRM & tools for seamless data sync and activation

Thousands of companies, including Context Therapeutics, are just a search away.